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Abstract The involvement of amino acid residues previously
proposed on the basis of structural data to have roles in the
ferroxidase and diamine oxidase activities of human ceruloplas-
min was investigated. Variants of human ceruloplasmin, in which
residues proposed to be involved in electron transfer and/or iron-
binding had been altered by site-directed mutagenesis, were
expressed in HEK293 cells. E633A and E597A/H602A variants
exhibited reduction in both activities by 50^60% compared to
recombinant wild-type ceruloplasmin. The variant E935A/
H940A had reduced ferroxidase activity (50%) but unaltered
diamine oxidase activity, whereas the variant E971A exhibited
enhanced diamine oxidase activity. For the L329M variant,
both activities were identical to those of wild-type cerulo-
plasmin. 1 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Ceruloplasmin (CP) is a member of the blue multi-copper
oxidase family of enzymes that includes laccase, ascorbate
oxidase, Fet3, bilirubin oxidase and hephaestin. The primary
structure of CP suggests that it also shares homologous do-
mains with blood coagulation factors V and VIII [1]. CP is
synthesised primarily in the liver and secreted into the blood
as a single-chain glycoprotein containing six prosthetic copper
atoms. In humans, circulating CP comprises 1046 amino
acids, exhibits an apparent molecular mass of V132 kDa
and has a normal plasma concentration of V0.3 mg/ml.
Greater than 95% of circulating copper is bound to CP; in
addition to its prosthetic copper atoms, CP loosely binds sev-
eral other copper ions [2].
CP can oxidise several substrates, including Fe2þ, aromatic
amines and phenols. CP is e⁄cient at oxidising Fe2þ in vitro
without generating free radicals: four one-electron oxidations
of Fe2þ are coupled to the four-electron reduction of O2 to
2H2O [3]. Although a potential role in oxidising biogenic
amines such as adrenaline has been proposed [4], several ob-
servations including a low Km for oxidation of Fe2þ (0.6 WM
[5]) indicate that iron may be the most important physiolog-
ical substrate of CP. CP can load iron into transferrin and
ferritin in vitro, although whether this occurs physiologically
is unknown.
Studies of individuals with aceruloplasminaemia, a fatal
disease characterised by an absence of plasma CP, have pro-
vided clear evidence that CP is involved in iron homeostasis
[6]. Investigations utilising animals, cultured cells, knockout
mice and yeast (e.g. [7^11]) have also highlighted an impor-
tant role for the ferroxidase activity of CP, though a precise
description of its functions in iron homeostasis has yet to be
resolved.
Determination of the three-dimensional structure of human
CP (hCP) [12] has furnished clues to its oxidase function. The
enzyme contains six L-barrel domains arranged in a triangular
array. Three of the six prosthetic copper atoms occupy mono-
nuclear type 1 sites in domains 2, 4 and 6 whereas the remain-
ing three form a trinuclear cluster at the interface of domains
1 and 6. The trinuclear cluster comprises a pair of coupled
type 3 copper atoms linked to a type 2 site. The arrangement
of the trinuclear cluster and domain 6 mononuclear site is
similar to that observed in ascorbate oxidase, laccase and
Fet3 [13,14]. The mononuclear sites are thought to be in-
volved in intramolecular electron transfer as the initial accep-
tors of reducing equivalents from the substrate, whereas bind-
ing and reduction of O2 occurs at the trinuclear cluster [3,15].
Studies of metal ion-soaked crystals have identi¢ed two
putative cation-binding sites in a negatively charged pocket
near to the copper atoms in domains 4 and 6 [16]. Binding
of Fe2þ at these sites has been proposed as the ¢rst step in the
ferroxidase catalytic mechanism, followed by oxidation of the
metal and translocation of the resultant Fe3þ [16]. Soaking
experiments with p-phenylenediamine suggest that aromatic
diamines bind at the bottom of domain 4, remote from the
mononuclear copper atom in this domain [17].
Analysis of the three-dimensional structure of hCP also
indicated potential electron transfer pathways between the
prosthetic copper atoms [15,16]. Here we report the e¡ects
on two of the enzymatic activities of hCP caused by the sub-
stitution of residues postulated, on the basis of structural
data, to be involved in intramolecular electron transfer and/
or iron-binding. As far as we are aware, this report represents
the ¢rst functional study of the importance of these residues
for the catalytic mechanism of ceruloplasmin.
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2. Materials and methods
2.1. Construction of hCP expression vector and site-directed
mutagenesis
A cDNA encoding hCP was subcloned from pBK-CMV-CP into
the plasmid pCI-neo (Promega, Madison, WI, USA) to produce the
vector pCI-neo-CP. Mutagenesis was performed using pCI-neo-CP as
the template and the oligonucleotides listed in Table 1. Vector (0.03
pmol) and oligonucleotide (25 pmol) were annealed, T4 DNA poly-
merase, T4 ligase, dNTPs and ATP were added, and extension and
ligation were e¡ected by incubating the mixture at 37‡C for 2 h. After
treatment with DpnI (0.1 U for 30 min at 37‡C), the reaction was used
to transform XLmutS (KanS) Escherichia coli cells (Stratagene, La
Jolla, CA, USA). Transformants were selected with ampicillin, and
appropriate colonies were identi¢ed by PCR and restriction endonu-
clease analysis (see Table 1 for restriction sites used as markers). All
mutations were con¢rmed by DNA sequence analysis of the vectors.
Enzymes were purchased from New England Biolabs (Beverly, MA,
USA).
2.2. Cell transfection and culture
A human embryonic kidney (HEK293) cell line was transfected
with each vector using DOTAP Liposomal Reagent (Boehringer
Mannheim, Mannheim, Germany) according to the manufacturer’s
instructions. Cells were cultured in a 5% CO2 atmosphere at 37‡C
in Dulbecco’s modi¢ed Eagle’s medium/Nutrient Mix F12 (DMEM/
F12; Life Technologies, Rockville, MD, USA) containing 5% (v/v)
newborn calf serum (Life Technologies), and clonal cell lines were
isolated by selection with 0.75 mg/ml Geneticin (Life Technologies).
For expression of hCP, cells were grown to V70% con£uence, the
serum-containing medium was removed, and the cells were washed
three times with DMEM/F12 without phenol red. The medium was
replaced with DMEM/F12 without phenol red containing 0.5% (v/v)
KnockOut SR serum-free supplement (Life Technologies) and 10 WM
CuSO4. Conditioned medium was harvested after 2^5 days, dialysed
against Chelex 100-treated H2O, concentrated, and frozen at 380‡C.
2.3. Western blot analysis
Protein samples (denatured/reduced) were resolved in SDS/7.5%
(w/v) polyacrylamide gels and electroblotted to nitrocellulose mem-
brane (Amersham Pharmacia Biotech, Buckinghamshire, UK). The
membrane was blocked with 10% (w/v) skim milk powder in Tris-
bu¡ered saline (TBS; 20 mM Tris^HCl, 154 mM NaCl, pH 7.0),
then incubated with goat anti-hCP antiserum (Sigma, St. Louis,
MO, USA) followed by washing and incubation with horseradish
peroxidase-conjugated rabbit anti-goat IgG (Sigma). Blots were devel-
oped with an ECL Western Blotting Kit (Amersham Pharmacia Bio-
tech).
2.4. Quanti¢cation of hCP
The concentration of recombinant hCP (rhCP) was determined by
competition ELISA. Puri¢ed hCP (Calbiochem, La Jolla, CA, USA)
was coated in 96-well microtitre plates (10 Wg/ml in TBS, 50 Wl per
well) overnight at 4‡C, then the wells were blocked for 1 h with 0.5%
(w/v) bovine serum albumin (Sigma) in TBS. Samples were pre-incu-
bated for 1 h with rabbit anti-hCP IgG (DAKO, Glostrup, Denmark),
then added to the blocked wells and incubated overnight at 4‡C. After
washing, alkaline phosphatase-conjugated mouse monoclonal anti-
rabbit IgG (Sigma) was added, and the plates were incubated for
45 min at room temperature. The wells were washed, and p-nitro-
phenyl phosphate liquid substrate (Sigma) was added. The reactions
were quenched with 3 M NaOH, and the A405 was measured in a
microtitre plate reader (Dynex Technologies, Ashford, Middlesex,
UK). The concentration of rhCP was determined from a standard
curve generated with puri¢ed hCP (Calbiochem). The limit of detec-
tion of the assay (3 S.D. above background) was 2.5 ng/ml, and the
assay was linear from 80 to 1200 ng/ml. All assays were performed in
triplicate.
2.5. Enzyme assays
Diamine oxidase activity was measured with the substrate O-diani-
sidine dihydrochloride (Sigma) [18,19]. Assays were performed at
37‡C with 1 Wg CP in 60 mM sodium acetate bu¡er, pH 5.0 contain-
ing 1.6 mM O-dianisidine. One unit of activity (U) is de¢ned as 1 Wmol
of O-dianisidine oxidised per min, based on a molar extinction coef-
¢cient, O540 = 9.6U103 M31 cm31. Ferroxidase activity was measured
using a discontinuous assay in which oxidation of Fe2þ is monitored
by quantifying the Fe2þ remaining in the solution after a set period of
time [20]. Assays were performed at 37‡C with 1 Wg CP in 0.42 M
sodium acetate bu¡er, pH 5.8 containing 24.5 WM Fe(NH4)2(SO4)2
(J.T. Baker Chemical, Phillipsburg, NJ, USA). Samples of the reac-
tions were removed at 10 min and 30 min and quenched with ferro-
zine (Sigma). The concentration of Fe2þ was determined from the
absorbance of the ferrozine^Fe2þ complex (O562 = 2.79U104 M31
cm31). As a negative control, CP was replaced by EDTA and, as a
positive control, it was replaced with Chelex 100-treated H2O. One
unit of activity (U) is de¢ned as 1 Wmol of Fe2þ oxidised per min.
3. Results and discussion
We assessed the e¡ect of various amino acid substitutions
upon the ferroxidase and diamine oxidase activities of hCP.
We replaced residues with alanine that have been postulated,
on the basis of structural analyses [12,16], to be potentially
involved in electron transfer and/or the labile cation-binding
sites of the protein. To our knowledge, this work represents
the ¢rst functional study of the importance of these residues
for the catalytic mechanism of CP. One of the residues of the
domain 2 mononuclear copper site (L329) was also replaced
by methionine.
Vectors encoding each of the mutated proteins and wild-
type hCP were used to stably transfect HEK293 cells. As the
presence of an intron has been shown to be requisite for
e⁄cient expression of CP in mammalian cells [21], we em-
ployed a vector containing a chimaeric intron upstream of
the cloning site. Cells transfected with the pCI-neo-CP vector
secreted wild-type rhCP, whereas mock-transfected cells did
not produce detectable amounts of the protein (Fig. 1). Like-
wise, each of the ¢ve mutated hCP proteins was also synthe-
sised and secreted (Fig. 1). In all cases, only a single band with
an apparent mass comparable to plasma-derived hCP (V130
kDa) was observed on Western blots, indicating that the se-
creted proteins were intact and undegraded. CP concentra-
tions in the conditioned medium were up to 2.5 Wg/ml as
determined by ELISA. Wild-type rhCP was functionally ac-
tive and able to oxidise both Fe2þ and O-dianisidine at rates
comparable to plasma-derived hCP (Fig. 2). Expression of the
ferroxidase and diamine oxidase activities was enhanced by
inclusion of CuSO4 in the medium, and both activities were
Table 1
Oligonucleotides used for site-directed mutagenesis of hCP
Oligonucleotides shown in upper case anneal to the coding (+)
strand, those in lower case to the non-coding (3) strand. Codons
specifying the mutated amino acids are shown in bold. Restriction
endonuclease sites incorporated into the oligonucleotides as markers
are underlined. The position of a unique SphI site that was knocked
out by the E935A/H940A oligonucleotide is also indicated.
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minimal in medium from cells cultured without additional
copper (data not shown).
The substitution E633A reduced both the ferroxidase and
diamine oxidase activities of hCP by V60% (Fig. 2), indicat-
ing that E633 may be important in the general catalytic mech-
anism of the enzyme. This ¢nding is consistent with the role
proposed for this residue in a potential electron transfer path-
way linking the mononuclear copper sites in domains 2 and 4
[16] (Fig. 3). However, the possible importance of the pathway
(Cu2-H324-(H-bond)-E633A-A634-D635-V636-H637-Cu4)
has been questioned because of the relatively long (3.7 AV )
distance between the NO atom of H324 and the side chain
ON atom of E633 [16]. Notably, the moderate resolution of
the structure determined by X-ray crystallography (V3.0 AV )
lends some uncertainty to the length of the hydrogen bond.
Additionally, Farver et al. [15] have suggested that the mono-
nuclear copper atoms in domains 2 and 4 may play little, if
any, role in catalysis and that electron transfer is not expected
to occur between any of the three mononuclear sites. This
view is not supported by our observations nor those of other
studies: analysis of sheep CP partially depleted of its type 1
copper atoms suggests that all three mononuclear sites act as
a pool and may be equally active in electron transfer [4,22].
Furthermore, destruction of the mononuclear site in domain 6
of hCP does not completely abolish diamine oxidase activity,
indicating that another type 1 site is able to contribute to the
catalytic mechanism [23]. The three mononuclear sites are in
su⁄cient proximity to permit electron transfer (withinV18 AV ).
Our results suggest that the proposed pathway may partici-
pate in shuttling electrons released during the oxidation of
both Fe2þ and diamines because the ferroxidase and diamine
oxidase activities of hCP were a¡ected to a similar degree by
the E633A substitution. As noted below, however, the mono-
nuclear copper in domain 2 of hCP has been shown recently
to have a very high potential that argues against a role for this
site in the human protein, though it is possible that it might
serve a function as a reservoir of electrons.
X-ray di¡raction studies of hCP have identi¢ed separate
binding sites for Fe2þ and diamines. The diamine-binding
site is located near W669 in domain 4. Consequently, the ox-
idation of diamine substrates may be achieved as electrons are
channeled through the domain 4 mononuclear copper centre
[17]. Crystal-soaking experiments indicate that Fe2þ binds at
two labile cation-binding sites in domains 4 and 6 [16]. Bind-
ing appears to occur through the displacement of non-pros-
thetic copper atoms followed by release of an electron and
translocation of Fe3þ to nearby holding sites. The ligands of
the domain 6 labile cation-binding site are E272, E935, H940
and D1025 (Fig. 3), of which E935 has also been implicated in
Fe3þ translocation [16,17]. This binding site, which is located
near that proposed to bind biogenic amines [17], is close to the
mononuclear copper centre in domain 6, and electrons could
easily be transferred to the copper atom through its H1026
ligand: subsequent transfer to the trinuclear centre is most
likely achieved via a Cys-His pathway similar to that observed
in ascorbate oxidase [24].
Substitutions of two of the amino acids comprising the pro-
posed domain 6 cation-binding site of hCP, E935 and H940,
was accompanied by an V50% decrease in ferroxidase activ-
ity, whereas diamine oxidase activity was una¡ected (Fig. 2).
This observation is consistent with the notion that one of the
two iron-binding sites on the molecule should be disrupted by
this substitution and provides functional evidence that the
domain 6 site is important for the ferroxidase mechanism of
hCP. Likewise, substitutions of E597 and H602, two of the
ligands proposed to constitute the labile cation-binding site in
domain 4 ^ the others are D684 and E971 (Fig. 3) ^ caused an
V50% decrease in the ferroxidase activity of hCP (Fig. 2).
However, in this case the diamine oxidase activity was also
Fig. 1. Expression of hCP by transfected HEK293 cells. HEK293
cells were stably transfected with either pCI-neo (mock transfection),
pCI-neo-CP (for expression of wild-type CP (rhCP)) or pCI-neo-CP
vectors in which the hCP cDNA had been altered by site-directed
mutagenesis to encode the denoted single or double amino acid sub-
stitutions. Conditioned medium (15 Wl) from clonal cell-lines was de-
natured and reduced, resolved by SDS^PAGE, and Western blotted
with antibodies against hCP. Bands were visualised by a chemilumi-
nescence-based method. The left-most lane contained plasma-derived
hCP (10 ng).
Fig. 2. Activities of recombinant wild-type and mutated hCP. The
ferroxidase and diamine oxidase activities of the recombinant pro-
teins were measured and are plotted relative to wild-type CP
(rhCP). The value 100% corresponds to an activity of 0.154 U/mg
for oxidation of Fe2þ and 0.114 U/mg for oxidation of O-dianisi-
dine. Data are the average of four measurements (duplicates for
preparations from two separate clonal cell lines), and error bars rep-
resent +1 S.D. Asterisks denote a signi¢cant di¡erence from rhCP:
*P6 0.01; **P6 0.005; ***P6 0.0005.
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reduced to a comparable degree. It is thus possible that the
local loss of charged residues might have perturbed the dia-
mine-binding site or perhaps even the environment of the
nearby mononuclear copper centre in domain 4.
Substitution of E971 had no detrimental e¡ect on ferrox-
idase activity and somewhat enhanced the diamine oxidase
activity (Fig. 2). This unanticipated result argues against the
proposal that E971 has roles both in electron transfer and as a
ligand of the labile cation-binding site in domain 4 [16] (Fig. 3).
The proposed pathway in this case follows the route Cu4-
H685-(H-bond)-E971-I972-D973-L974-H975-Cu6, thus link-
ing the mononuclear copper sites in domains 4 and 6, both
of which are active redox centres [3]. It therefore appears that
E971 is not a requisite ligand of the iron-binding site in do-
main 4 and that an alternative pathway may exist for shuttling
electrons from the domain 4 to domain 6 mononuclear copper
centre, possibly via the copper centre in domain 2.
We also tested the e¡ect of substituting L329, a non-coor-
dinating residue in the domain 2 type 1 copper centre (Fig. 3),
with Met. The presence of Leu at this position is unusual in
that the site is typically occupied by an axial Met residue in
type 1 copper centres. Other multi-copper oxidases that con-
tain Leu at the corresponding position are Fet3 and certain
laccase isozymes [3]. In these enzymes, as in hCP, the copper
atom is bound by the side chains of two His residues and a
Cys residue. These tri-coordinate sites have a relatively high
reduction potential (possibly exceeding 1 V), and it has been
argued that in hCP the copper atom remains in a permanently
reduced and, hence, redox-inactive state [3,25]. No e¡ect on
either ferroxidase or diamine oxidase activity was observed for
the L329M substitution (Fig. 2), an alteration that might be
expected to decrease the reduction potential of the copper
centre. This observation concurs with a recent study of hCP
expressed in yeast, which reported that the L329M substitu-
tion did not alter either the ferroxidase activity or spectro-
scopic properties of the molecule [23]. Presumably, this sub-
stitution is necessary but not su⁄cient to restore functional
activity to this copper-binding site.
In conclusion, using site-directed mutagenesis and analysis
of rhCP expressed in a human cell line, we have investigated
the functional importance of certain residues that have been
proposed, based on structural data, to play a key role in
the ferroxidase and diamine oxidase functions of this pro-
tein.
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Fig. 3. Structural locations of residues mutated in hCP. Model shows the labile cation-binding sites in domains 4 and 6 of hCP and the pro-
posed electron transfer pathways linking the three mononuclear copper sites. The prosthetic copper atoms are depicted as red spheres and metal
atoms bound at the labile sites as grey spheres. The side chains of the residues that were mutated to Ala in this study are coloured light green
and are labelled. The model was generated from the published coordinates for hCP [12,16], using the program Swiss-PdbViewer (available on-
line at www.expasy.ch/spdbv/mainpage.html).
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